2026 John R. Mascola: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	163	70	67	48	46	638	102518
Medicine	163	685	626	395	352	638	102518

Research.com Recognitions

2026 - Research.com Immunology in United States Leader Award
2025 - Research.com Immunology in United States Leader Award
2017 - Member of the National Academy of Medicine (NAM)
Member of the Association of American Physicians
Member of the Association of American Physicians
Member of the Association of American Physicians
Member of the Association of American Physicians

Overview

John R. Mascola is affiliated with ModeX Therapeutics in the United States and has contributed extensively to research in medicine, immunology, and microbiology. Their work spans multiple subfields including infectious diseases, virology, immunology, epidemiology, and radiology, nuclear medicine, and imaging.

The scientist's research covers a range of main topics such as HIV research and treatment, SARS-CoV-2 and COVID-19 research, monoclonal and polyclonal antibodies research, HIV/AIDS drug development and treatment, immune cell function and interaction, viral gastroenteritis research and epidemiology, and studies on animal virus infections.

Frequently publishing in venues recognized in the scientific community, John R. Mascola has contributed to:

bioRxiv (Cold Spring Harbor Laboratory)
UNC Libraries
Science Translational Medicine
Cell Reports
Nature Communications

Their collaborative work includes frequent co-authorship with researchers such as Peter D. Kwong, Barney S. Graham, Nicole A. Doria-Rose, Tongqing Zhou, and Adrian B. McDermott.

Notable recent publications include:

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report, 2020, New England Journal of Medicine
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness, 2020, Nature
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates, 2020, New England Journal of Medicine
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination, 2020, New England Journal of Medicine
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19, 2021, New England Journal of Medicine

John R. Mascola has been recognized with memberships in professional organizations including the National Academy of Medicine (NAM) since 2017 and the Association of American Physicians.

Best Publications

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Lindsey R. Baden;Hana M El Sahly;Brandon J Essink;Karen Kotloff

7148
Citations
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Lisa A. Jackson;Evan J. Anderson;Nadine G. Rouphael;Paul C. Roberts

3419
Citations
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.

Pengfei Wang;Manoj S. Nair;Lihong Liu;Sho Iketani;Sho Iketani

2148
Citations
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Xueling Wu;Zhi Yong Yang;Yuxing Li;Carl Magnus Hogerkorp

2090
Citations
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

John R. Mascola;Gabriela Stiegler;Thomas C. VanCott;Hermann Katinger

1698
Citations
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.

Kizzmekia S. Corbett;Darin K. Edwards;Sarah R. Leist;Olubukola M. Abiona

1589
Citations
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Tongqing Zhou;Ivelin Georgiev;Xueling Wu;Zhi Yong Yang

1405
Citations
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

Ming Li;Feng Gao;John R. Mascola;Leonidas Stamatatos

1310
Citations
Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

John R. Mascola;Mark G. Lewis;Gabriela Stiegler;Dawn Harris

1212
Citations
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Hua-Xin Liao;Rebecca Lynch;Tongqing Zhou;Feng Gao;Feng Gao

1175
Citations
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

Kizzmekia S Corbett;Barbara Flynn;Kathryn E Foulds;Joseph R Francica

1112
Citations
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Jason S. McLellan;Marie Pancera;Chris Carrico;Jason Gorman

1061
Citations
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

Johannes F. Scheid;Hugo Mouquet;Niklas Feldhahn;Michael S. Seaman

1043
Citations
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Jinghe Huang;Gilad Ofek;Leo Laub;Mark K. Louder

1022
Citations
Human skin Langerhans cells are targets of dengue virus infection.

Shuenn-Jue L. Wu;Geraldine Grouard-Vogel;Wellington Sun;John R. Mascola

894
Citations
Structure and immune recognition of trimeric pre-fusion HIV-1 Env

Marie Pancera;Tongqing Zhou;Aliaksandr Druz;Ivelin S. Georgiev

867
Citations
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Nicole A. Doria-Rose;Chaim A. Schramm;Jason Gorman;Penny L. Moore

809
Citations
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

Alicia T. Widge;Nadine G. Rouphael;Lisa A. Jackson;Evan J. Anderson

799
Citations
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

Hadi M. Yassine;Jeffrey C. Boyington;Patrick M. McTamney;Patrick M. McTamney;Chih Jen Wei;Chih Jen Wei

749
Citations
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

Michael S. Seaman;Holly Janes;Natalie Hawkins;Lauren E. Grandpre

742
Citations
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

Nicole Doria-Rose;Mehul S. Suthar;Mat Makowski;Sarah O’Connell

672
Citations
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

Pengfei Wang;Manoj S Nair;Lihong Liu;Sho Iketani;Sho Iketani

385
Citations

Frequent Co-Authors

Peter D. Kwong Columbia University Medical Center

Gary J. Nabel ModeX Therapeutics

Barney S. Graham Morehouse School of Medicine

Mark K. Louder National Institute of Allergy and Infectious Diseases

Sijy O'Dell National Institute of Allergy and Infectious Diseases

Robert T. Bailer National Institute of Allergy and Infectious Diseases

Richard T. Wyatt Scripps Research Institute

David C. Montefiori Duke University

Nicole A. Doria-Rose National Institute of Allergy and Infectious Diseases

Tongqing Zhou National Institutes of Health

External Links

Personal website of John R. Mascola

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For those interested in immunology, pursuing related healthcare degrees can expand career opportunities significantly. Many professionals start with accelerated nursing pathways before specializing. For example, exploring an acnp programs can provide advanced clinical skills tailored to acute care, ideal for working with complex immunological conditions.

Individuals aiming to fast-track their nursing career might consider a nurse practitioner accelerated program. These intensive tracks help qualified nurses gain advanced practice credentials swiftly, supporting roles in immunology-related patient care and research.

For those without a nursing background, the best online rn programs for non nurses offer accessible entry points into nursing. These programs provide the foundational knowledge needed for clinical roles and further specialization in immunological science.

Additionally, the easiest absn to get into can be a practical choice for quickly transitioning into nursing practice. Success in these accelerated programs can pave the way to careers that intersect with immunology, such as infection control and immunotherapy nursing.